Amgen Inc. shares jumped in extended trading after the maker of osteoporosis drug Prolia easily beat Wall Street's second-quarter profit expectations and hiked its 2015 financial forecast. Amgen, based in Thousand Oaks, California, said Thursday it sees strong momentum for the second half of the year, with three new drugs launching, new approvals for a couple expected soon and experimental drugs for migraines, heart failure and preventing bone fractures in or near the final rounds of patient testing.